Rubius Therapeutics to Announce Second Quarter 2018 Financial Results
Aug. 21, 2018
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, plans to report second quarter 2018 financial results on Friday, August 31, 2018.
The company will not be conducting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com or follow us on Twitter.
Media Contact: Dan Budwick 1AB, Inc. +1 (973) 271-6085 firstname.lastname@example.org
Investor Contact: Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 229-6122 email@example.com